Endometrial Cancer FIGO 2023 Stage (with molecular) — free guideline decision tool
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Histologic type | Non-aggressive (G1–2 endometrioid) |
|---|---|
| Anatomic extent | Confined to endometrium/polyp, no myometrial invasion |
| Molecular subtype | Unknown / not done |
→FIGO stageStage IA
- FIGO 2023 stage：Stage IA
- Management direction：Surgical staging (total hysterectomy + BSO ± sentinel/systematic nodes); adjuvant therapy by risk stratification (histology/grade/myometrial invasion/LVSI/molecular) deciding observation, vaginal brachytherapy, external-beam pelvic radiation or chemotherapy
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage
| Histologic type | Aggressive (G3, serous, clear-cell, carcinosarcoma, undifferentiated, etc.) |
|---|---|
| Anatomic extent | Distant metastasis (IVC) |
| Molecular subtype | NSMP |
→FIGO stageStage IVCmNSMP
- FIGO 2023 stage：Stage IVCmNSMP (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only)
- Management direction：Surgery (aim for optimal cytoreduction) + platinum chemotherapy ± radiation; advanced/recurrent may add immunotherapy (dMMR/MMRd: dostarlimab/pembrolizumab; pMMR: combined with lenvatinib)
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage
Common questions
What is Endometrial Cancer FIGO 2023 Stage (with molecular)?
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
How is Endometrial Cancer FIGO 2023 Stage (with molecular) calculated? What is the core formula?
Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
When is Endometrial Cancer FIGO 2023 Stage (with molecular) used?
Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
What are the key clinical points for Endometrial Cancer FIGO 2023 Stage (with molecular)?
FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009. POLEmut confined to the corpus is downstaged to IAmPOLEmut (excellent prognosis, supports de-escalation regardless of LVSI/grade). p53abn confined disease with any myometrial invasion is upstaged to IICmp53abn (poor prognosis, escalate adjuvant therapy). MMRd and NSMP are recorded as subscripts but do not change the stage; for stage III/IV molecular subtype is recorded only.
What are the limits and cautions when using Endometrial Cancer FIGO 2023 Stage (with molecular)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Endometrial Cancer FIGO 2023 Stage (with molecular) calculated in practice? Can you show a worked example?
Inputs: Histologic type Non-aggressive (G1–2 endometrioid), Anatomic extent Confined to endometrium/polyp, no myometrial invasion, Molecular subtype Unknown / not done → Result: FIGO stage Stage IA（FIGO 2023 stage: Stage IA, Management direction: Surgical staging (total hysterectomy + BSO ± sentinel/systematic nodes); adjuvant therapy by risk stratification (histology/grade/myometrial invasion/LVSI/molecular) deciding observation, vaginal brachytherapy, external-beam pelvic radiation or chemotherapy, Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage） Inputs: Histologic type Aggressive (G3, serous, clear-cell, carcinosarcoma, undifferentiated, etc.), Anatomic extent Distant metastasis (IVC), Molecular subtype NSMP → Result: FIGO stage Stage IVCmNSMP（FIGO 2023 stage: Stage IVCmNSMP (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only), Management direction: Surgery (aim for optimal cytoreduction) + platinum chemotherapy ± radiation; advanced/recurrent may add immunotherapy (dMMR/MMRd: dostarlimab/pembrolizumab; pMMR: combined with lenvatinib), Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage）
Run Endometrial Cancer FIGO 2023 Stage (with molecular) now
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.